Profound Medical Corp. announced that Texas Prostate, led by Dr. James Cochran, has performed its 100th TULSA Procedure at Dallas Medical Center. This milestone highlights the adoption of Profound's MRI-guided prostate therapy technology under a collaborative model that has reportedly increased procedure volumes.
Key takeaways
Texas Prostate, led by Dr. James Cochran, has performed its 100th TULSA Procedure at Dallas Medical Center's MRI suite.
Dr. Cochran stated that transitioning from a private pay to a Medicare model via collaboration with Dallas Medical Center increased TULSA Procedure numbers by 500%.
The TULSA Procedure is performed using the TULSA-PRO system to treat prostate cancer and benign prostatic hyperplasia (BPH).
Profound's CEO Arun Menawat commented that Texas Prostate's model bridges private-pay practices and Medicare-participating hospitals to accelerate adoption of the TULSA Procedure.
The TULSA Procedure uses robotically controlled directional ultrasound with real-time MRI thermography, resulting in no procedural blood loss and no overnight hospital stay.
Profound also commercializes Sonalleve, an MRI-guided therapy for pain palliation of bone metastases, desmoid tumors, osteoid osteoma, uterine fibroids, and adenomyosis.